Variability in derived parameters of furosemide pharmacokinetics
Tóm tắt
The pharmacokinetics of furosemide in normal man reported from a number of investigators show great discrepancies. We have evaluated the effect on derived pharmacokinetic parameters of furosemide of using different weighting factors or fewer data points to fit the same set of data to an exponential equation, or using noncompartmental analysis. Terminal half-lives of furosemide differed vastly, as did the volume of distribution, but to a lesser extent. The plasma clearance was rather consistent with the different methods used. Thus the discrepancies of the pharmacokinetics of furosemide may, in large part, be due to different methods of analysis of the data. The terminal half-life was most subject to errors of method and the plasma clearance the least.
Tài liệu tham khảo
F. Andreasen, H. E. Hansen, and E. Mikkelsen. Pharmacokinetics of furosemide in anephric patients and in normal subjects.Eur. J. Clin. Pharmacol. 13:41–48 (1978).
F. Andreasen and E. Mikkelsen. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure.Eur. J. Clin. Pharmacol. 12:15–22 (1977).
B. Beermann, E. Dalén, and B. Lindstrom. Elimination of furosemide in healthy subjects and in those with renal failure.Clin. Pharmacol. Ther. 22:70–78 (1977).
R. A. Branch, C. J. C. Roberts, M. Homeida, and D. Levine. Determinants of response to furosemide in normal subjects.Br. J. Clin. Pharmacol. 4:121–127 (1977).
P. Chennavasin, R. Seiwell, D. C. Brater, and W. M. M. Liang. Pharmacodynamic analysis of the furosemide-probenecid interaction in man.Kidney Int. 16:187–195 (1979).
R. E. Cutler, A. W. Forrey, T. G. Christopher, and B. M. Kimpel. Pharmacokinetics of furosemide in normal subjects and functionally anephric patients.Clin. Pharmacol. Ther. 15:588–596 (1974).
M. Homeida, C. Roberts, and R. A. Branch. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man.Clin. Pharmacol. Ther. 22:402–409 (1977).
J. Honari, A. Blair, and R. Cutler. Effects of probenecid on furosemide kinetics and natriuresis in man.Clin. Pharmacol. Ther. 22:395–401 (1977).
M. R. Kelly, R. E. Cutler, A. W. Forrey, and B. M. Kimpel. Pharmacokinetics of orally administered furosemide.Clin. Pharmacol. Ther. 15:178–186 (1973).
J. R. Lawrence, A. F. Ansari, H. L. Elliott, D. J. Sumner, G. R. Brunton, and R. Whiting. Kinetic and dynamic comparison of piretanide and furosemide.Clin. Pharmacol. Ther. 23:558–565 (1978).
A. Rane, J. P. Villeneuve, W. J. Stone, A. S. Nies, G. R. Wilkinson, and R. A. Branch. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia.Clin. Pharmacol. Ther. 24:199–207 (1978).
W. Rupp and P. Hajdu. Pharmacokinetics and pharmacodynamics of a diuretic agent. In H. J. Dengler (ed.),Pharmacological and Clinical Significance of Pharmacokinetics, F. K. Schutlauer Verlag, Stuttgart, 1970.
D. E. Smith, D. C. Brater, E. T. Lin, and L. Z. Benet. Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation.J. Pharmacokinet. Biopharm. 7:265–274 (1979).
W. J. Tilstone and A. Fine. Furosemide kinetics in renal failure.Clin. Pharmacol. Ther. 23:644–650 (1978).
L. Z. Benet. Pharmacokinetics/pharmacodynamics of furosemide in man: a review.J. Pharmacokinet. Biopharm. 7:1–27 (1979).
R. E. Cutler and A. D. Blair. Clinical pharmacokinetics of frusemide.Clin. Pharmacokinet. 4:279–296 (1979).
P. J. Fell and M. T. Stevens. Pharmacokinetics—use and abuses.Eur. J. Clin. Pharmacol. 8:241–248 (1975).
J. G. Wagner. Pharmacokinetic parameters estimated from intravenous data by uniform methods and some of their uses.J. Pharmacokinet. Biopharm. 5:161–182 (1977).
W. J. Westlake. Use of statistical methods in evaluation ofin vivo performance of dosage forms.J. Pharm. Sci. 62:1579–1589 (1973).
C. M. Metzler, G. L. Elfring, and A. J. McEwen. A package of computer programs for pharmacokinetic modeling (abstract).Biometrics 30:562 (1974).
A. J. Sedman and J. G. Wagner. CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.J. Pharm. Sci. 65:1006–1010 (1976).
H. G. Boxenbaum, S. Riegelman, and R. M. Elashoff. Statistical estimations in pharmacokinetics.J. Pharmacokinet. Biopharm. 2:123–148 (1974).
P. Chennavasin, R. Seiwell, and D. C. Brater. Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man.J. Pharmacol. Exp. Ther. 215:77–81 (1980).
L. Z. Benet and R. L. Galeazzi. Noncompartmental determination of the steady-state volume of distribution.J. Pharm. Sci. 68:1071–1074 (1979).
H. I. Glass and A. C. deGarreta. The quantitative limitations of exponential curve fitting.Phys. Med. Biol. 16:119–130 (1971).
H. P. Wijnand and C. J. Timmer. Curve fitting and modeling in pharmacokinetics: all programs are equal, but some programs are more equal than others.J. Pharmacokinet. Biopharm. 7:681–684 (1979).
K. T. Muir and S. Riegelman. Curve fitting and modeling in pharmacokinetics.J. Pharmacokinet., Biopharm. 7:685–687 (1979).
T. Ishizaki, M. Watanabe, and N. Morishita. The effect of assay methods of plasma levels and pharmacokinetics of theophylline: HPLC and EIA.Br. J. Clin. Pharmacol. 7:333–341 (1979).
R. G. Nayak, R. D. Smith, J. H. Chamberlain, A. Polk, A. F. Delong, T. Herozeg, P. B. Chemburlear, R. S. Joslin, and N. H. Reavey-Canwell. Methaqualone pharmacokinetics after single and multiple-dose administration in man.J. Pharmacokinet. Biopharm. 2:107–121 (1974).
M. Gibaldi and D. Perrier.Pharmacokinetics. Marcel Dekker, New York, 1975, pp. 307–308.
J. G. Wagner.Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications, Hamilton, Ill., 1975, pp. 288–290.
P. V. Pedersen. Curve fitting and modeling in pharmacokinetics and some practical experiences in NONLIN and a new program FUNFIT.J. Pharmacokinet. Biopharm. 5:513–530 (1977).
C. M. Metzler and G. L. Elfring. Curve fitting and modeling in pharmacokinetics: a response.J. Pharmacokinet. Biopharm. 6:443–446 (1978).
C. C. Peck, L. Sheiner, S. Beal, and A. Nichols. Pharmacokinetic data analysis using extended least-squares nonlinear regression.Clin. Pharmacol. Ther. 27:277–278 (1980).